Thomson Reuters unveils new regulatory intelligence solution at DIA 2012

NewsGuard 100/100 Score

The Intellectual Property & Science division of Thomson Reuters unveiled Cortellis for Regulatory Intelligence at the DIA 2012 Annual Meeting in Philadelphia today. This new offering is the next generation of Thomson Reuters IDRAC™, the company's best-in-class regulatory intelligence tool that provides pharmaceutical professionals with reliable and accurate global regulatory information to gain competitive advantage and minimize regulatory risks.

Cortellis for Regulatory Intelligence is a comprehensive regulatory solution  that  helps regulatory affairs professionals make timely and more informed decisions by providing them with exclusive regulatory information for multi-country filings, comparing existing and emerging competitive products, preparing for committee meetings and inspections, and keeping up-to-date on regulatory changes as they happen.

"Our business depends on understanding the global regulatory landscape and the continually evolving submission approval requirements," said Rick Riegel, CEO of Liquent. "By using Cortellis for Regulatory Intelligence, we can assure our clients that our knowledge is supplemented by the industry's leading regulatory intelligence database.  In addition, it provides the opportunity to explore new ways of incorporating that knowledge into our own solutions via the available API's in the Cortellis platform."

This new regulatory intelligence solution enables companies to more quickly and easily leverage the comprehensive and enhanced regulatory content via Thomson Reuters Cortellis™, the premiere Life Sciences platform.

Cortellis delivers impressive search speeds and more relevant results due to an all-new search engine in a highly intuitive user interface. The search engine allows for rapid free-text searching, making it possible for users to search across the platform's entire regulatory database without the need to design complex search strategies, while custom filters are available to increase accuracy. Cortellis will also make valuable information more accessible and is compatible with mobile devices, including smartphones and tablet devices, providing a more interactive user experience, and the freedom to stay informed while on the go.

Here is what some pharmaceutical professionals have said after using Cortellis for Regulatory Intelligence:

  • "Cortellis for Regulatory Intelligence is 'remarkably' different in a good way."
  • "This search platform is so different compared to standard IDRAC, it's almost incomparable! I think I will use it in a completely different way. Very nice!"
  • "We have explored Cortellis for Regulatory Intelligence and we are very pleased with the easy sorting capabilities."

"We are very excited to announce the launch of Cortellis for Regulatory Intelligence and think it has the power to transform the way the industry approaches and utilizes pharmaceutical regulatory intelligence," said Jon Brett-Harris, executive vice president of Life Sciences at Thomson Reuters. "The industry's needs for accessing regulatory intelligence are changing and Thomson Reuters is responding to the new demands. Cortellis for Regulatory Intelligence not only allows our customers to make stronger, better informed decisions, but will greatly improve their ability to be compliant."

SOURCE Thomson Reuters

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Georgetown study raises concerns over aspirin's role in breast cancer treatment